中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

31 records (took 0.029 seconds)

    FUNCTIONAL CHARACTERIZATION OF MYO-INOSITOL MONOPHOSPHATASE
    1.
    发明申请
    FUNCTIONAL CHARACTERIZATION OF MYO-INOSITOL MONOPHOSPHATASE 审中-公开
    MYO-INOSITOL单磷酸酶的功能特征

    公开(公告)号：WO2004101779A2

    公开(公告)日：2004-11-25

    申请号：PCT/EP2004005190

    申请日：2004-05-13

    Applicant: JANSSEN PHARMACEUTICA NV ,  BALEMANS WENDY MIA ALBERT ,  MOECHARS DIEDERIK WILLEM ELISA ,  STECKLER THOMAS HORST WOLFGANG ,  CRYNS KIM

    Inventor： BALEMANS WENDY MIA ALBERT ,  MOECHARS DIEDERIK WILLEM ELISA ,  STECKLER THOMAS HORST WOLFGANG ,  CRYNS KIM

    IPC: C12N9/16 ,  G01N33/573

    CPC classification number: A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356 ,  C12N9/16 ,  G01N33/573

    Abstract: This invention relates to the functional characterization of myo-inositol monophosphatase 2 (IMPA2), one of the enzymes acting in the phosphatidyl inositol signaling pathway. In particular, the present invention provides evidence that IMPA2 is associated with depression- and anxiety inducing conditions, in particular anxiety and affective disorders. In a first aspect the present invention provides the use of an IMPA2 enzyme in an assay to identify anti-anxiety or an anti-depression compounds. In particular to the use of an isolated polynucleotide encoding said IMPA2 protein, wherein said IMPA2 protein is preferably being selected from polynucleotides encoding the mouse, rat or human IMPA2 enzyme. It is thus an object of the present invention to provide a method for identifying anti-anxiety or anti-depression compounds wherein said compounds are capable of enhancing neuronal plasticity, said method comprising the steps of: a) providing a composition comprising an IMPA2 protein; b) contacting the IMPA2 protein with the test compound; and c) measuring the activity of the IMPA2 protein wherein a decrease in the IMPA2 activity in the presence of the test compound is an indicator of an anti-anxiety or anti-depression compound. In these assays the activity of the IMPA2 protein is assessed by measuring the hydrolysis of myo-inositol 1-phosphate to generate inositol and inorganic phosphate, in particular by measuring the accumulation of either myo-inositol monophosphate product in the form of radiolabeled inositol or inorganic phosphate (Pi) in the form of radiolabeled Pi or in a colorimetric assay. The compositions comprising the IMPA2 protein could either be cellular extracts, whole cells or organisms expressing the IMPA2 proteins according to the invention.

    Abstract translation: 本发明涉及作用于磷脂酰肌醇信号通路的酶之一的肌醇单磷酸酯酶2（IMPA2）的功能表征。 特别地，本发明提供证据表明IMPA2与抑郁和焦虑诱导病症特别是焦虑和情感障碍有关。 在第一方面，本发明提供了IMPA2酶在测定中用于鉴定抗焦虑或抗抑郁化合物的用途。 特别是使用编码所述IMPA2蛋白的分离的多核苷酸，其中所述IMPA2蛋白优选选自编码小鼠，大鼠或人IMPA2酶的多核苷酸。 因此，本发明的目的是提供一种用于鉴定抗焦虑或抗抑郁化合物的方法，其中所述化合物能够增强神经元可塑性，所述方法包括以下步骤：a）提供包含IMPA2蛋白质的组合物; b）使IMPA2蛋白质与测试化合物接触; 和c）测量IMPA2蛋白的活性，其中在测试化合物存在下IMPA2活性的降低是抗焦虑或抗抑郁化合物的指标。 在这些测定中，IMPA2蛋白的活性通过测量肌醇-1-磷酸肌醇的水解来产生肌醇和无机磷酸酯来评估，特别是通过测量放射性标记的肌醇或无机形式的肌醇单磷酸酯产物的积累 磷酸盐（Pi）以放射性标记的32 P的形式或在比色测定中。 包含IMPA2蛋白质的组合物可以是表达本发明的IMPA2蛋白质的细胞提取物，全细胞或生物体。

    5.
    发明专利
    未知

    公开(公告)号：AT353649T

    公开(公告)日：2007-03-15

    申请号：AT04726520

    申请日：2004-04-08

    Applicant: JANSSEN PHARMACEUTICA NV

    Inventor： STECKLER THOMAS HORST WOLFGANG ,  JANSSENS FRANS EDUARD JANSSEN ,  LEENAERTS JOSEPH ELISABETH ,  FERNANDEZ-GADEA FRANCISCO J ,  GOMEZ-SANCHEZ ANTONIO ,  MEERT THEO FRANS

    IPC: A61K31/454 ,  A61K31/506 ,  A61P25/22 ,  A61P25/24 ,  A61K31/4545 ,  A61K31/496 ,  A61P3/04

    Abstract: The present invention relates to the use of 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives according to Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof as selective non-peptide delta-opioid agonists for use in the prevention and/or treatment of various central nervous system disorders, in particular as selective antidepressant and anxiolytic non-peptide delta-opioid agonists. In particular are claimed compounds according to Formula (I) in which A=B is C-O or SO 2 , X is a covalent bond, R 1 is allyloxy, alkyloxyalkyl, Ar or NR 9 R 10 , wherein R 9 and R 10 each independently are hydrogen or Ar; or A=B and R 1 together form a benzoxazolyl radical; p is zero, R 3 is benzyl optionally substituted with hydroxy, alkyl or alkyloxycarbonyl and R 4 and R 5 each are hydrogen.

    ПРОИЗВОДНЫЕ ИЗОКСАЗОЛИНА В КАЧЕСТВЕ АНТИДЕПРЕССАНТОВ
    8.
    发明专利
    ПРОИЗВОДНЫЕ ИЗОКСАЗОЛИНА В КАЧЕСТВЕ АНТИДЕПРЕССАНТОВ 未知

    公开(公告)号：EA006747B1

    公开(公告)日：2006-04-28

    申请号：EA200300915

    申请日：2002-02-13

    Applicant: JANSSEN PHARMACEUTICA NV

    Inventor： ANDRES-GIL JOSE IGNACIO ,  FERNANDEZ-GADEA FRANCISCO JAVI ,  ALCAZAR-VACA MANUEL JESUS ,  CID-NUNEZ JOSE MARIA ,  PASTOR-FERNANDEZ JOAQUIN ,  MEGENS ANTONIUS ADRIANUS HENDRICUS PETRUS ,  HEYLEN GODELIEVE IRMA CHRISTIN MARIA ,  LANGLOIS XAVIER JEAN MICHEL ,  BAKKER MARGARETHA HENDRICA MARI ,  STECKLER THOMAS HORST WOLFGANG

    IPC: C07D498/04 ,  A61K31/454 ,  A61K31/495 ,  A61K31/496 ,  A61K31/538 ,  A61P3/04 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  C07D261/20 ,  C07D498/14 ,  C07D519/00

    Abstract: Изобретениеотноситсяк замещеннымизоксазолинамформулы (I)гдеХ=СН, N-R, S илиО; Rи Rпредставляютсобойнекоторыеопределенныезаместители, Pir представляетсобойнеобязательнозамещенныйпиперидильныйилипиперазильныйрадикали Rпредставляетсобойнеобязательнозамещеннуюароматическуюгомоциклическуюилигетероциклическуюсистему, включающуючастичноилиполностьюгидрированнуюуглеводороднуюцепьдлиноймаксимумв 6 атомовуглерода, спомощьюкоторойциклическаясистемаприсоединяетсяк радикалу Pir, икотораяможетсодержатьодинилинесколькогетероатомов, выбранныхизО, N и S; способуихполучения, фармацевтическимкомпозициям, содержащимтакиесоединения, ик ихприменениюв качествелекарственногосредства, вчастности, длялечениядепрессиии/илитревогии нарушениймассытела. Неожиданнопоказано, чтосоединенияпоизобретениюобладаютактивностьюингибированияобратногопоглощениясеротонина (5-НТ) всочетаниис другойактивностьюантагонистовα-адренорецепторови обнаруживаютсильнуюантидепрессивнуюактивность, небудучиседативными. Соединенияпоизобретениютакжеподходятдлялечениябольныхс тревожнымирасстройствамии нарушениямимассытела. Изобретениетакжеотноситсяк новомусочетаниюзамещенныхизоксазолиновс антидепрессивнойактивностьюи/илианксиолитическойактивностьюи/илиактивностьюрегулированиямассытелас антидепрессантами, анксиолитикамии/илиантипсихотическимисредствамидляцелейповышенияэффективностии/илиускоренияначаладействия.

    Functional characterization of myo-inositol monophosphatase
    10.
    发明专利
    Functional characterization of myo-inositol monophosphatase 未知

    公开(公告)号：AU2004238995A1

    公开(公告)日：2004-11-25

    申请号：AU2004238995

    申请日：2004-05-13

    Applicant: JANSSEN PHARMACEUTICA NV

    Inventor： BALEMANS WENDY MIA ALBERT ,  STECKLER THOMAS HORST WOLFGANG ,  CRYNS KIM ,  MOECHARS DIEDERIK WILLEM ELISA

    IPC: C12N15/55 ,  C12N9/16 ,  C12Q1/68 ,  G01N33/573

    Abstract: This invention relates to the functional characterization of myo-inositol monophosphatase 2 (IMPA2), one of the enzymes acting in the phosphatidyl inositol signaling pathway. In particular, the present invention provides evidence that IMPA2 is associated with depression- and anxiety inducing conditions, in particular anxiety and affective disorders. In a first aspect the present invention provides the use of an IMPA2 enzyme in an assay to identify anti-anxiety or an anti-depression compounds. In particular to the use of an isolated polynucleotide encoding said IMPA2 protein, wherein said IMPA2 protein is preferably being selected from polynucleotides encoding the mouse, rat or human IMPA2 enzyme. It is thus an object of the present invention to provide a method for identifying anti-anxiety or anti-depression compounds wherein said compounds are capable of enhancing neuronal plasticity, said method comprising the steps of: a) providing a composition comprising an IMPA2 protein; b) contacting the IMPA2 protein with the test compound; and c) measuring the activity of the IMPA2 protein wherein a decrease in the IMPA2 activity in the presence of the test compound is an indicator of an anti-anxiety or anti-depression compound. In these assays the activity of the IMPA2 protein is assessed by measuring the hydrolysis of myo-inositol 1-phosphate to generate inositol and inorganic phosphate, in particular by measuring the accumulation of either myo-inositol monophosphate product in the form of radiolabeled inositol or inorganic phosphate (Pi) in the form of radiolabeled 32 Pi or in a colorimetric assay. The compositions comprising the IMPA2 protein could either be cellular extracts, whole cells or organisms expressing the IMPA2 proteins according to the invention.

Patent Agency Ranking